Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas — (May 7, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored […]
Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in Diabetes AUSTIN, Texas — (April 29, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming […]
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes AUSTIN, Texas — (March 25, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming 2025 […]
AUSTIN, Texas — (March 4, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 17-19, 2025 in Milan, Italy. In […]
Researching Novel Diabetes Gene Therapy Using Potentially Re-Dosable Non-Viral Delivery System Strategic Collaboration with CDMO Partner Positions Genprex as a Thought-Leader in Diabetes Market AUSTIN, Texas — (Feb. 19, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the […]
Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development AUSTIN, Texas — (Feb. 18, 2025) —Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with […]
Ryan Confer, President and Chief Executive Officer at Genprex, sat down with the Marathon Money podcast to discuss the Company’s pipeline of gene therapies for cancer and diabetes. Watch the interview here: https://www.youtube.com/watch?v=blIpam7eBTc
Company’s CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs AUSTIN, Texas — (Sept. 23, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in […]
Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes AUSTIN, Texas — (Sept. 4, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced […]
Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes AUSTIN, Texas — (Aug. 8, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing […]